BlackRock Investment Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-708,015
| Closed | -$248K | – | 4042 |
|
|
2016
Q3 | $248K | Buy |
708,015
+3,060
| +0.4% | +$1.07K | ﹤0.01% | 3219 |
|
|
2016
Q2 | $329K | Buy |
704,955
+45,237
| +7% | +$21.1K | ﹤0.01% | 3207 |
|
|
2016
Q1 | $897K | Buy |
659,718
+96,569
| +17% | +$131K | ﹤0.01% | 2561 |
|
|
2015
Q4 | $828K | Buy |
563,149
+2,568
| +0.5% | +$3.78K | ﹤0.01% | 2729 |
|
|
2015
Q3 | $886K | Sell |
560,581
-10,072
| -2% | -$15.9K | ﹤0.01% | 2679 |
|
|
2015
Q2 | $970K | Buy |
570,653
+139,017
| +32% | +$236K | ﹤0.01% | 2784 |
|
|
2015
Q1 | $600K | Buy |
431,636
+88,135
| +26% | +$123K | ﹤0.01% | 2862 |
|
|
2014
Q4 | $519K | Sell |
343,501
-2,108
| -0.6% | -$3.19K | ﹤0.01% | 2985 |
|
|
2014
Q3 | $712K | Buy |
345,609
+2,056
| +0.6% | +$4.24K | ﹤0.01% | 2756 |
|
|
2014
Q2 | $1.05M | Buy |
343,553
+19,114
| +6% | +$58.5K | ﹤0.01% | 2570 |
|
|
2014
Q1 | $811K | Buy |
324,439
+43,437
| +15% | +$109K | ﹤0.01% | 2663 |
|
|
2013
Q4 | $1.39M | Buy |
281,002
+3,174
| +1% | +$15.7K | ﹤0.01% | 2272 |
|
|
2013
Q3 | $633K | Buy |
277,828
+60,497
| +28% | +$138K | ﹤0.01% | 2767 |
|
|
2013
Q2 | $482K | Buy |
+217,331
| New | +$482K | ﹤0.01% | 2872 |
|
BlackRock Investment Management's RXII Position: Q4 2016 in Review
BlackRock Investment Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 708,015 shares — an estimated $248K sold.
BlackRock Investment Management first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $1.39M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- BlackRock Investment Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- BlackRock Investment Management sold 708,015 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $248K.
- BlackRock Investment Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- BlackRock Investment Management's GALENA BIOPHARMA INC COM position peaked at $1.39M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.